Nektar shows durability of Opdivo combo in 18-month update

Nektar Therapeutics has presented 18-month data on its NKTR-214-Opdivo combination in first-line melanoma. The phase 1/2 results show the efficacy seen at 12 months has persisted, providing early evidence to support Nektar’s belief NKTR-214 can drive durable, deepening responses.